|
1
|
Li C, Lei S, Ding L, Xu Y, Wu X, Wang H,
Zhang Z, Gao T, Zhang Y and Li L: Global burden and trends of lung
cancer incidence and mortality. Chin Med J (Engl). 136:1583–1590.
2023.PubMed/NCBI
|
|
2
|
Huang J, Deng Y, TinM S, Lok V, Ngai CH,
Zhang L, Lucero-Prisno DE III, Xu W, Zheng ZJ, Elcarte E, et al:
Distribution, risk factors, and temporal trends for lung cancer
incidence and mortality: A global analysis. Chest. 161:1101–1111.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tandberg DJ, Tong BC, Ackerson BG and
Kelsey CR: Surgery versus stereotactic body radiation therapy for
stage I non-small cell lung cancer: A comprehensive review. Cancer.
124:667–678. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
LeeC S, Shu CC, Chen YC, Liao KM and Ho
CH: Tuberculosis treatment incompletion in patients with lung
cancer: Occurrence and predictors. Int J Infect Dis. 113:200–206.
2021. View Article : Google Scholar
|
|
5
|
Tartour E and Zitvogel L: Lung cancer:
Potential targets for immunotherapy. Lancet Respir Med. 1:551–563.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Yan B and He S: Advances and
challenges in the treatment of lung cancer. Biomed Pharmacother.
169:1158912023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu S, Bishop WR and Liu M: Differential
effects of cell cycle regulatory protein p21(WAF1/Cip1) on
apoptosis and sensitivity to cancer chemotherapy. Drug Resist
Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chin EN, Sulpizio A and Lairson LL:
Targeting STING to promote antitumor immunity. Trends Cell Biol.
33:189–203. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pérez-Herrero E and Fernández-Medarde A:
Advanced targeted therapies in cancer: Drug nanocarriers, the
future of chemotherapy. Eur J Pharm Biopharm. 93:52–79. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jurisic V, Vukovic V, Obradovic J,
Gulyaeva LF, Kushlinskii NE and Djordjević N: EGFR polymorphism and
survival of NSCLC patients treated with TKIs: A systematic review
and meta-analysis. J Oncol. 2020:19732412020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Obradovic J, Todosijevic J and Jurisic V:
Side effects of tyrosine kinase inhibitors therapy in patients with
non-small cell lung cancer and associations with EGFR
polymorphisms: A systematic review and meta-analysis. Oncol Lett.
25:622022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishimoto A: Effective combinations of
anti-cancer and targeted drugs for pancreatic cancer treatment.
World J Gastroenterol. 28:3637–3643. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujita E, Nagao Y, Kaneko K, Nakazawa S
and Kuroda H: The antitumor and antibacterial activity of the
Isodon diterpenoids. Chem Pharm Bull (Tokyo). 24:2118–2127. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei WJ, Zhu B, Si Y, Guo T, Kang J and Dai
L: Cytotoxic ent-kaurane diterpenoids from rabdosia rubescens. Chem
Biodivers. 19:e2022004972022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jia XB, Zhang Q, Xu L, Yao WJ and Wei L:
Lotus leaf flavonoids induce apoptosis of human lung cancer A549
cells through the ROS/p38 MAPK pathway. Biol Res. 54:72021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin X, Sun PP, Hong Y, Yu L and Li S:
Puerarin induces apoptosis in A549 cells. Zhongguo Ying Yong Sheng
Li Xue Za Zhi. 33:466–469. 2017.(In Chinese). PubMed/NCBI
|
|
17
|
Zhao C, Qin G, Gao W, Chen J, Liu H, Xi G,
Li T, Wu S and Chen T: Potent proapoptotic actions of
dihydroartemisinin in gemcitabine-resistant A549 cells. Cell
Signal. 26:2223–2233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou T, Qin R, Shi S, Zhang H, Niu C, Ju G
and Miao S: DTYMK promote hepatocellular carcinoma proliferation by
regulating cell cycle. Cell Cycle. 20:1681–1691. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oredsson SM: Polyamine dependence of
normal cell-cycle progression. Biochem Soc Trans. 31:366–370. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guarracino MR, Xanthopoulos P, Pyrgiotakis
G, Tomaino V, Moudgil BM and Pardalos PM: Classification of cancer
cell death with spectral dimensionality reduction and generalized
eigenvalues. Artif Intell Med. 53:119–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Efimova I, Catanzaro E, Van der Meeren L,
Turubanova VD, Hammad H, Mishchenko TA, Vedunova MV, Fimognari C,
Bachert C, Coppieters F, et al: Vaccination with early ferroptotic
cancer cells induces efficient antitumor immunity. J Immunother
Cancer. 8:e0013692020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martinvalet D: ROS signaling during
granzyme B-mediated apoptosis. Mol Cell Oncol. 2:e9926392015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Al-Khayal K, Alafeefy A, Vaali-Mohammed
MA, Mahmood A, Zubaidi A, Al-Obeed O, Khan Z, Abdulla M and Ahmad
R: Novel derivative of aminobenzenesulfonamide (3c) induces
apoptosis in colorectal cancer cells through ROS generation and
inhibits cell migration. BMC Cancer. 17:42017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Z, Xiao J, Liu M, Cui J, Lian B, Sun Y
and Li C: Notch3 regulates ferroptosis via ROS-induced lipid
peroxidation in NSCLC cells. FEBS Open Bio. 12:1197–1205. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang CX, Chen LH, Zhuang HB, Shi ZS, Chen
ZC, PanJ P and Hong ZS: Auriculasin enhances ROS generation to
regulate colorectal cancer cell apoptosis, ferroptosis, oxeiptosis,
invasion and colony formation. Biochem Biophys Res Commun.
587:99–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Son Y, Kim S, Chung HT and Pae HO:
Reactive oxygen species in the activation of MAP kinases. Methods
Enzymol. 528:27–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rochette L, Dogon G, Rigal E, Zeller M,
Cottin Y and Vergely C: Lipid peroxidation and iron metabolism: Two
corner stones in the homeostasis control of ferroptosis. Int J Mol
Sci. 24:4492022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Molavinia S, Dayer D, Khodayar MJ,
Goudarzi G and Salehcheh M: Suspended particulate matter promotes
epithelial-to-mesenchymal transition in alveolar epithelial cells
via TGF-β1-mediated ROS/IL-8/SMAD3 axis. J Environ Sci (China).
141:139–150. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu T, Sun L, Zhang Y, Wang Y and Zheng J:
Imbalanced GSH/ROS and sequential cell death. J Biochem Mol
Toxicol. 36:e229422022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
LiF J, Long HZ, Zhou ZW, Luo HY, Xu SG and
Gao LC: System Xc−/GSH/GPX4 axis: An important
antioxidant system for the ferroptosis in drug-resistant solid
tumor therapy. Front Pharmacol. 13:9102922022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Y, Li Y, Li J and Chen W: Ethyl
carbamate triggers ferroptosis in liver through inhibiting GSH
synthesis and suppressing Nrf2 activation. Redox Biol.
53:1023492022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miao Y, Chen Y, Xue F, Liu K, Zhu B, Gao
J, Yin J, Zhang C and Li G: Contribution of ferroptosis and GPX4′s
dual functions to osteoarthritis progression. EBioMedicine.
76:1038472022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma P, Xiao H, Yu C, Liu J, Cheng Z, Song
H, Zhang X, Li C, Wang J, Gu Z and Lin J: Enhanced cisplatin
chemotherapy by iron oxide nanocarrier-mediated generation of
highly toxic reactive oxygen species. Nano Lett. 17:928–937. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nie J, Lin B, Zhou M, Wu L and Zheng T:
Role of ferroptosis in hepatocellular carcinoma. J Cancer Res Clin
Oncol. 144:2329–2337. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jia B, Li J, Song Y and Luo C:
ACSL4-mediated ferroptosis and its potential role in central
nervous system diseases and injuries. Int J Mol Sci. 24:100212023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hou L, Li X, Su C, Chen K and Qu M:
Current status and prospects of research on ischemia-reperfusion
injury and ferroptosis. Front Oncol. 12:9207072022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li X, Zou Y, Fu YY, Xing J, Wang KY, Wan
PZ and Zhai XY: A-lipoic acid alleviates folic acid-induced renal
damage through inhibition of ferroptosis. Front Physiol.
12:6805442021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li S, Lu Z, Sun R, Guo S, Gao F, Cao B and
Aa J: The role of SLC7A11 in cancer: Friend or foe? Cancers
(Basel). 14:30592022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng X, Wang Y, Liu L, Lv C, Liu C and Xu
J: SLC7A11, a potential therapeutic target through induced
ferroptosis in colon adenocarcinoma. Front Mol Biosci.
9:8896882022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Moloney JN and Cotter TG: ROS signalling
in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gerami P, Kim D, Compres EV, Zhang B, Khan
AU, Sunshine JC, Quan VL and Busam K: Clinical, morphologic, and
genomic findings in ROS1 fusion Spitz neoplasms. Mod Pathol.
34:348–357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lv C, Fu S, Dong Q, Yu Z, Zhang G, Kong C,
Fu C and Zeng Y: PAGE4 promotes prostate cancer cells survive under
oxidative stress through modulating MAPK/JNK/ERK pathway. J Exp
Clin Cancer Res. 38:242019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Guimarães LM, Coura BP, Gomez RS and Gomes
CC: The molecular pathology of odontogenic tumors: Expanding the
spectrum of MAPK pathway driven tumors. Front Oral Health.
2:7407882021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li H, Han G, Li X, Li B, Wu B, Jin H, Wu L
and Wang W: MAPK-RAP1A signaling enriched in hepatocellular
carcinoma is associated with favorable tumor-infiltrating immune
cells and clinical prognosis. Front Oncol. 11:6499802021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pereira L, Igea A, Canovas B, Dolado I and
Nebreda AR: Inhibition of p38 MAPK sensitizes tumour cells to
cisplatin-induced apoptosis mediated by reactive oxygen species and
JNK. EMBO Mol Med. 5:1759–1774. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu J, Yu M and Li J: PKC-δ promotes
IL-1β-induced apoptosis of rat chondrocytes and via activating JNK
and P38 MAPK pathways. Cartilage. 194760352311814462023.(Epub ahead
of print).
|
|
47
|
Zhao Q, Yu M, Li J, Guo Y, Wang Z, Hu K,
Xu F, Liu Y, Li L, Wan D, et al: GLUD1 inhibits hepatocellular
carcinoma progression via ROS-mediated p38/JNK MAPK pathway
activation and mitochondrial apoptosis. Discov Oncol. 15:82024.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang X, Tan X, Zhang J, Wu J and Shi H:
The emerging roles of MAPK-AMPK in ferroptosis regulatory network.
Cell Commun Signal. 21:2002023. View Article : Google Scholar : PubMed/NCBI
|
